RecruitingNot ApplicableNCT06724653
Tapering Heart Failure Medication in Patients With Heart Failure With Recovered Ejection Fraction; Open Label Prospective Random Trial
Sponsor
Chungnam National University Hospital
Enrollment
150 participants
Start Date
Mar 6, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Study start date is on Nov 27th 2024. A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.
Eligibility
Min Age: 18 Years
Inclusion Criteria9
- initial echocardiogram ejection fraction less than 40%
- follow up echocardiogram ejection fraction over 50% and LVEDD index normal range
- NTprobnp criteria
- eGFR ≥60 ; less 440
- eGFR 45-59: less 980
- eGFR 30-44; less 1220
- eGFR \< 30 : less 5300
- in HD; no criteria for NTproBNP
- on more than 3 heart failure medication ( RAS blocker, beta blocker, mineral corticoid receptor antagonist, SGLT 2 inhibitor)
Exclusion Criteria7
- under age 18 year
- uncontrolled BP ( over 150/90)
- coronary revascularization within 6 months
- significant valve disease
- arrhythmia requiring rate control
- CKD with albuminuria ( over 30mg/g)
- Pregnancy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGRAS blocker tapering group
RAS blocker tapering out
DRUGBeta blocker tapering out
Beta blocker tapering out group
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06724653
Related Trials
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060928 locations
Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany
NCT066755526 locations
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
NCT072320301 location
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370638 locations
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
NCT06991257130 locations